Chemical Information
Antiviral agent ID	DrugRepV_1905
Antiviral agent name	PHA-690509
IUPAC Name	(2S)-2-(4-acetamidophenyl)-N-(5-propan-2-yl-1,3-thiazol-2-yl)propanamide
SMILES (canonical)	CC(C)C1=CN=C(S1)NC(=O)C(C)C2=CC=C(C=C2)NC(=O)C
SMILES (isomeric)	C[C@@H](C1=CC=C(C=C1)NC(=O)C)C(=O)NC2=NC=C(S2)C(C)C
Molecular Formula	C17H21N3O2S
Molecular Weight (g/mol)	331.434
InChl	InChI=1S/C17H21N3O2S/c1-10(2)15-9-18-17(23-15)20-16(22)11(3)13-5-7-14(8-6-13)19-12(4)21/h5-11H,1-4H3,(H,19,21)(H,18,20,22)/t11-/m0/s1
Synonyms	PHA-690509 | (2S)-2-[4-(Acetylamino)phenyl]-N-(5-isopropyl-1,3-thiazol-2-yl)propanamide
Structural Information
Clinical Information
Biological Information
Primary Indication (Disease Category)	Non Infectious Disease
Primary Indication (Disease)	Cancer
Secondary Indication	Zika virus (ZIKV) NA PRVABC-59 (2015 Puerto Rican strain)
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	SNB-19 glioblastoma
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	1 MOI
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Pre infection (1 hour)
Secondary Indication (Duration of drug delivery)	24 hours
Secondary Indication (Drug concentration)	92 μM
Secondary Indication (Cell based assay)	Western blot
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	Protein Expression [ Decrease Band intensity ]
Reference	Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, Tcw J, Kouznetsova J, Ogden SC, Hammack C, Jacob F,.Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.Nat Med. 2016 Oct;22(10):1101-1107. doi: 10.1038/nm.4184. Epub 2016 Aug 29. PMID:27571349
Comment	The identified compounds that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells